Gilead Sciences, Inc. (NASDAQ:GILD) was the target of a large increase in short interest in the month of October. As of October 15th, there was short interest totalling 15,046,053 shares, an increase of 13.8% from the September 28th total of 13,219,532 shares. Based on an average trading volume of 6,495,748 shares, the short-interest ratio is presently 2.3 days. Approximately 1.2% of the shares of the stock are short sold.
GILD has been the topic of a number of analyst reports. ValuEngine upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a report on Tuesday, July 3rd. BidaskClub upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a report on Tuesday, July 10th. Zacks Investment Research upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $86.00 target price on the stock in a report on Wednesday, July 18th. Robert W. Baird cut Gilead Sciences from an “outperform” rating to a “neutral” rating and set a $79.00 target price on the stock. in a report on Thursday, July 26th. Finally, Wells Fargo & Co increased their target price on Gilead Sciences from $89.00 to $95.00 and gave the company an “outperform” rating in a report on Thursday, July 26th. Thirteen investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. Gilead Sciences currently has an average rating of “Buy” and a consensus price target of $87.84.
In related news, Director John C. Martin sold 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 4th. The stock was sold at an average price of $74.16, for a total value of $3,708,000.00. Following the sale, the director now owns 3,067,762 shares in the company, valued at approximately $227,505,229.92. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders sold 150,000 shares of company stock worth $11,502,500. Insiders own 1.30% of the company’s stock.
Shares of Gilead Sciences stock opened at $69.74 on Friday. Gilead Sciences has a fifty-two week low of $64.27 and a fifty-two week high of $89.54. The firm has a market cap of $88.95 billion, a price-to-earnings ratio of 8.15, a price-to-earnings-growth ratio of -3.47 and a beta of 1.01. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.92 and a current ratio of 3.00.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, topping analysts’ consensus estimates of $1.63 by $0.21. Gilead Sciences had a return on equity of 40.28% and a net margin of 7.12%. The company had revenue of $5.60 billion for the quarter, compared to analyst estimates of $5.44 billion. During the same quarter in the prior year, the company posted $2.27 EPS. Analysts expect that Gilead Sciences will post 6.6 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, December 28th. Shareholders of record on Friday, December 14th will be paid a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.27%. The ex-dividend date is Thursday, December 13th. Gilead Sciences’s dividend payout ratio is presently 26.64%.
About Gilead Sciences
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Featured Story: Using the New Google Finance Tool
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.